Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WEE1 | P30291 | 16/20 | 0.64 |
| ▸ | SIK2 | Q9H0K1 | 2/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | SIK1 | P57059 | 1/20 | 0.39 |
| ▸ | SIK3 | Q9Y2K2 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29859721 | 1.00 | WEE1 (0.64) | WEE1SIK2CSF1RSIK1SIK3 | |
| SCHEMBL23263115 | 0.94 | WEE1 (0.69) | WEE1SIK2 | |
| SCHEMBL29859410 | 0.94 | WEE1 (0.69) | WEE1SIK2 | |
| SCHEMBL21373451 | 0.92 | WEE1 (0.68) | WEE1SIK2 | |
| SCHEMBL29506539 | 0.92 | WEE1 (0.68) | WEE1SIK2 | |
| SCHEMBL29506525 | 0.91 | WEE1 (0.68) | WEE1SIK2KCNH2EGFR | |
| SCHEMBL21373416 | 0.91 | WEE1 (0.68) | WEE1SIK2KCNH2EGFR | |
| SCHEMBL23246115 | 0.90 | WEE1 (0.78) | WEE1 | |
| SCHEMBL23263117 | 0.90 | WEE1 (0.65) | WEE1SIK2 | |
| SCHEMBL29859616 | 0.90 | WEE1 (0.65) | WEE1SIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240091233-A1 | USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER | Impact Therapeutics (Shanghai), Inc (CN) | 2024-03-21 | — | — | US | claimed |
| US-20240091233-A1 | USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER | Impact Therapeutics (Shanghai), Inc (CN) | 2024-03-21 | — | — | US | disclosed |
| WO-2021073491-A1 | DIHYDROIMIDAZO PYRIMIDO PYRIMIDINONE COMPOUND | 上海瑛派药业有限公司 | 2021-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240091233-A1 | USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER | WEE1, WEE2, EZH2 | WEE1 1/4885SIK2 93/4885CSF1R 2455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.